The size of the global cancer monoclonal antibodies market is forecasted to be worth USD 78.55 billion by 2026 from USD 45.97 billion in 2021, registering a CAGR of 11.31% between 2021 to 2026.
Cancer is a severe disease-causing million of death worldwide every year. Cancer starts from a single cell and genetically transforms a normal cell into a tumor cell and is gradually spread to other cells. With the dramatic increase in the number of people affected by cancer, many pharmaceutical players invested in monoclonal antibodies. However, while the drugs are used to treat cancer, drugs like chemotherapy agents have adverse side effects on normal and cancerous cells. Therefore, it prompted the increased usage of monoclonal antibodies for the treatment of cancer.
Monoclonal Antibodies (mAbs) are mono-specific antibody bodies comprising identical immune cells clones of a single parent cell and directed to specific cellular targets. Thus, monoclonal antibodies are highly customizable due to their particular nature and can play a crucial role in eliminating cancerous cells while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment. Monoclonal Antibodies could offer less toxic and efficient therapeutic alternatives to patients emerging in recent years. Monoclonal Antibodies are used to treat a wide array of autoimmune, inflammatory, and especially cancer.
MARKET DRIVERS:
A few of the significant factors driving the global cancer monoclonal antibodies market are the increasing prevalence of cancer, increasing investment in R&D of genomic studies, and increasing progress and preference towards the specificity of monoclonal antibodies to attack cancer.
According to the WHO, cancer is the second leading cause of death globally, registering for an estimated 9.9 million deaths, or 1 in 6 deaths, in 2019. Cancer-associated with prostate, colorectal & liver is the most common cancer in men, while cancer associated with colorectal, lung, cervical & thyroid cancer are most commonly affected by women. Therefore, the increase in data should inform any national cancer policy, leading to the rise in the percentage of people choosing cancer treatment. In the health sector, cancer is one of the biggest concerns. Therefore, the increased use of monoclonal antibodies for cancer treatment is boosting this market.
The dramatic increase in cancer patients has led many pharmaceutical players to invest in the monoclonal antibodies market. Increasing investment in R&D of genomic studies, technological advancements in genetic sequencing and target gene selection, and a specificity of monoclonal antibodies to target only the cancer cells with no side effects are some of the market's driving forces. The increased prevalence of cancer is the key driver of the monoclonal antibodies market. It is expected to grow lucratively in the next five years with health products in the pipeline.
There is a rapid increase in research and the development of genomic studies due to the growing demand. This has led to a rapid rise in the growth of the monoclonal cancer antibodies market. In addition, it is also believed that the increase in the prevalence of breast cancer promotes the development of the global cancer monoclonal antibodies market.
MARKET RESTRAINTS:
However, following regulatory guidelines for cancer-related monoclonal antibodies is a very rigorous process in most parts of the world. The guidelines provide a complete description of the manufacturing processes, including quality, good manufacturing practices, process validation, and potential for degradation, and the need for stability studies. Therefore, globally, there is a strict regulatory scenario like the US FDA, European Medicines Agency (EMA), and Korean FDA. Cancer antibodies also face similar restrictions in gaining approval for monoclonal antibodies in the market. As this is a long process, it is considered one of the main hurdles for this market.
The growth of the cancer monoclonal antibodies market is a long period of research and development before clinical trials, the increase in mAbs failures in clinical trials, and the high cost of the products defying the market's growth rate.
Impact of COVID-19 on the global cancer monoclonal antibodies market:
The World Health Organization (WHO) declared the COVID-19 pandemic a public health emergency issue affecting millions of people and has spread to every corner of the world. The pandemic has affected all sectors, including the medical field. During the COVID-19 outrage, the pharma industry was more bothered about developing the COVID-19 vaccine. As a result, cancer monoclonal antibodies' research and development activities have taken a drop, even though the demand for cancer monoclonal antibodies is stable and high before the pandemic. During the pandemic lockdown, there has been a slight decline in the cancer monoclonal antibodies. However, the market position is forecasted to fall in its place by the end of 2021.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Application, Type, Conjugate Cancer Therapies, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Amgen, Genmab, GlaxoSmithKline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics & Spectrum Pharmaceuticals. |
This research report on the global cancer monoclonal antibodies market has been segmented and sub-segmented based on application, type, conjugate cancer therapies, and region.
Cancer Monoclonal Antibodies Market - By Application:
Based on the application, the breast cancer application segment held the highest share in the cancer monoclonal antibodies market in 2020. Growing exposure to harmful radiation, insufficient physical exercise, and expanding unhealthy lifestyles mobilize the market growth. In addition, large companies' growth in investments, increasing government initiatives, and rising female population push the market forward.
Cancer Monoclonal Antibodies Market - By Type:
Based on type, the murine antibodies account for the lion's share in the cancer monoclonal antibodies type during the forecast period. The murine antibodies play a significant role in advancing present-day antibody production procedures and developing the potential usage of immunoglobins for various applications propelling the market growth.
The fully humanized antibodies segment is the quickest growing, with a CAGR rate during the forecasting framework. In addition, the integration of advanced technologies like yeast or phase display showcases their market growth.
Cancer Monoclonal Antibodies Market - By Conjugate Cancer Therapies:
The radioimmunotherapy segment is forecasted to play a dominating role in the cancer monoclonal antibodies market during the forecast period due to the increasing number of cancer patients with the growing number of hospitals and diagnostic centers.
Cancer Monoclonal Antibodies Market - By Region:
Geographically, the North American market dominated the global cancer monoclonal antibodies market and is estimated to be worth USD 17.53 billion by 2026 due to a well-maintained healthcare infrastructure, increased government expenditure for infection control and management, and the rising commonness of life-style related diseases. In addition, the North American area is regarded to show the same growth due to its rise in cancer research and technology development. During the forecast period, the U.S. cancer monoclonal antibodies market is forecasted to be growing at a promising growth rate and the Canadian market is expected to showcase a healthy CAGR.
The European market is anticipated to show a prominent growth rate of 10.9% during the forecast period owing to increased common awareness of autoimmune diseases, cancer population, and rising funding in research and development in the monoclonal antibodies market. In Europe, UK and Germany are expected to register major market share.
The cancer monoclonal antibodies market in the APAC region was worth USD 6.71 billion in 2021. The Asia-Pacific market is regarded to increase significantly due to increased spending capacity and the growing knowledge among the patients.
The Latin America regional market is predicted to have a moderate growth rate during the forecast period.
KEY MARKET PLAYERS:
The highly customizable nature of the monoclonal antibodies attracts various organizations, research institutes, and multinational companies to use it as a tool to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, GlaxoSmithKline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics & Spectrum Pharmaceuticals.
RECENT MARKET DEVELOPMENTS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Application
5.1.1 Liver
5.1.2 Breast
5.1.3 Brain
5.1.4 Blood
5.1.5 Hodgkins and Non-Hodgkins lymphoma
5.1.6 Colorectal
5.1.7 Leukaemia
5.1.8 Others
5.2 By Type
5.2.1 Murine Antibodies
5.2.2 Chimeric and Humanised Antibodies
5.2.3 Fully Humanized Antibodies
5.3 Conjugate Cancer Therapies
5.3.1 Immunoliposome
5.3.2 Radioimmunotherapy
5.3.3 ADEPT
5.3.4 Immunocytokines
5.3.5 Others
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Amgen
8.3 Genmab
8.4 Glaxosmithkline
8.5 Bristol Meyer Squibb
8.6 Eli Lilly
8.7 Immunogen
8.8 Novartis
8.9 Seattle Genetics
8.10 Spectrum Pharmaceuticals
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
